Vir Biotechnology, Inc. (VIR)
Stock Price:
$31.44 USD
-2.39 (-7.06%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
After-hours: $31.20 -0.24 (-0.76%) Oct 30, 7:59 PM
Key Info
| Market Cap |
3.99B |
| Revenue (ttm) |
75.09M |
| Net Income (ttm) |
-220.49M |
| Shares Out |
127.05M |
| EPS (ttm) |
-14.64 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$31.44 |
| Previous Close |
$33.83 |
| Change ($) |
-2.39 |
| Change (%) |
-7.06% |
| Day's Open |
33.51 |
| Day's Range |
30.35 - 33.51 |
| Day's Volume |
981,581 |
| 52-Week Range |
11.65 - 75.00 |
More Stats
| Market Cap |
3.99B |
| Enterprise Value |
3.44B |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
127.05M |
| Float |
47.17M |
| EPS (basic) |
0.19 |
| EPS (diluted) |
-14.64 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
7.24M |
| Short Ratio |
6.05 |
| Short % of Float |
15.34% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
53.20 |
| PB Ratio |
7.46 |
| Revenue |
75.09M |
| Operating Income |
-212.40M |
| Net Income |
-220.49M |
| Free Cash Flow |
n/a |
| Net Cash |
550.64M |
| Net Cash / Share |
4.33 |
| Gross Margin |
-179.76% |
| Operating Margin |
-282.86% |
| Profit Margin |
-293.60% |
| FCF Margin |
n/a |
| ROA |
-22.96% |
| ROE |
-45.69% |
| ROIC |
-97.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (8)
| Buy |
5 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
1 |
| Sell |
0 |
Price Target
$54.14*
(72.20% upside)
Low
24.0
Current: $31.44
High
100.0
Target: 54.14
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 8.09 | 10.67 | 2.71 |
| Revenue Growth | -24.16% | 293.94% | - |
| Gross Profit | 8.09 | 10.67 | 2.71 |
| Operating Income | -178 | -119 | -81.50 |
| Net Income | -175 | -116 | -69.85 |
| Shares Outstanding | 30.35 | 7.67 | 2.15 |
| Earnings Per Share | -5.76 | -15.12 | -32.45 |
| Operating Cash Flow | -130 | -94.10 | -66.38 |
| Capital Expenditures | -8.94 | -8.17 | -2.74 |
| Free Cash Flow | -139 | -102 | -69.12 |
| Cash & Equivalents | 390 | 109 | 188 |
| Net Cash / Debt | 390 | 109 | 188 |
| Assets | 512 | 192 | 252 |
| Liabilities | 88.13 | 61.64 | 27.96 |
| Book Value | 424 | -179 | -68.92 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Vir Biotechnology, Inc. |
| Country |
United States |
| Employees |
253 |
| CEO |
George A. Scangos |
Stock Information
| Ticker Symbol |
VIR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: VIR |
| IPO Date |
October 11, 2019 |
Description
Vir Biotechnology, a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.